Compare Gilead Sciences, Inc. (GILD) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Rigetti Computing Inc — how do they compare? Gilead Sciences, Inc. trades at $134.63 (market cap $163.51B), while Rigetti Computing Inc trades at $14.21 (market cap $5.07B). The key difference: Gilead Sciences, Inc. is far larger — about 32.3× Rigetti Computing Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| GILD | RGTI | |
|---|---|---|
Market Cap | $163.51B | $5.07B |
Sector | Health | Technology |
52-Week High | $155.80 | $56.34 |
52-Week Low | $108.22 | $12.90 |
Enterprise Value | $178.05B | $4.66B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rigetti Computing (RGTI) trades at $14.72, down 8.63% with bearish technical signals. The company shows negative profitability with -2,253.59% net margin and -$216.21M net loss in 2025, though quarterly EPS has beaten expectations. Analyst sentiment remains strong with 85.71% buy ratings and $32.67 consensus target. Recent news highlights quantum computing sector volatility and Rigetti's infrastructure advancements amid ongoing cash burn.
The stock offers high-risk growth potential in quantum computing with significant analyst upside but faces substantial execution risks. Key challenges include persistent losses, cash burn of $22.82M in 2025, and intense sector competition. Investment suitability depends on risk tolerance for pre-revenue technology ventures with long commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
